揭示内分泌治疗耐药HER2+/ER+乳腺癌的脆弱性
Shaymaa Bahnassy1, Hillary Stires2, Lu Jin1
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Endocrinology
|October 28, 2023
概括
对内分泌疗法耐药HER2+/ER+乳腺癌的新模型揭示了脆弱性. 将GPX4抑制剂与抗HER2药物的结合显示出治疗这种具有挑战性的乳腺癌亚型的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 过度表达HER2的乳腺癌 (BCa) 与ER阳性 (HER2+/ER+) 显示对内分泌疗法 (ET) 的内在耐药性.
- 与HER2+/ER+ BCa患者相比,HER2+/ER+ BCa患者对ET的反应不那么有效.
- 相当数量的HER2+/ER+患者接受ET单疗法,这对临床提出了挑战.
研究的目的:
- 开发和表征在体外模型的ET-耐药 (ETR) HER2+/ER+BCa.
- 为了确定ETR HER2+/ER+ BCa.中的潜在治疗漏洞.
- 了解ET耐药HER2+/ER+BCa的独特表型和分子变化.
主要方法:
- 开发了两种长期雌激素剥夺 (LTED) 细胞系 (BT474和MDA-MB-361),以模仿AI耐药性.
- 增长试验,PAM50亚型,基因组,转录组和单细胞RNA测序分析.
- 涉及GPX4抑制剂和抗HER2剂联合治疗的功能研究.
主要成果:
- MM361 LTEDs表现出更快的增长,ER损失和增加的HER2表达; BT474 LTEDs表现出更慢的增长,保持ER和HER2表达.
- 两种LTED变种都对富尔韦斯特兰特的反应有所减少.
- MM361 LTEDs 显示了转录因子/染色体修饰剂的突变,转向非光的表型,以及升调的脂质代谢和铁相关基因 (例如,GPX4).
- 与GPX4抑制剂和抗HER2药物的联合治疗在两种模型中都诱导了显著的细胞死亡.
结论:
- 开发的BT474和MM361AI耐药模型代表了HER2+/ER+BCa的不同的表型.
- 改变的脂质代谢和铁亡重塑被确定为ET耐药HER2+/ER+BCa的关键漏洞.
- 针对GPX4与抗HER2药物结合,为ETR HER2+/ER+乳腺癌提供了潜在的治疗策略.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Endocrine Signaling
64.4K
Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
64.4K


